Fc receptor but not complement binding is important in antibody protection against HIV
Top Cited Papers
- 1 September 2007
- journal article
- Published by Springer Nature in Nature
- Vol. 449 (7158) , 101-104
- https://doi.org/10.1038/nature06106
Abstract
Most successful vaccines elicit neutralizing antibodies and this property is a high priority when developing an HIV vaccine. Indeed, passively administered neutralizing antibodies have been shown to protect against HIV challenge in some of the best available animal models. For example, antibodies given intravenously can protect macaques against intravenous or mucosal SHIV (an HIV/SIV chimaera) challenge and topically applied antibodies can protect macaques against vaginal SHIV challenge. However, the mechanism(s) by which neutralizing antibodies afford protection against HIV is not understood and, in particular, the role of antibody Fc-mediated effector functions is unclear. Here we report that there is a dramatic decrease in the ability of a broadly neutralizing antibody to protect macaques against SHIV challenge when Fc receptor and complement-binding activities are engineered out of the antibody. No loss of antibody protective activity is associated with the elimination of complement binding alone. Our in vivo results are consistent with in vitro assays indicating that interaction of Fc-receptor-bearing effector cells with antibody-complexed infected cells is important in reducing virus yield from infected cells. Overall, the data suggest the potential importance of activity against both infected cells and free virus for effective protection against HIV.Keywords
This publication has 31 references indexed in Scilit:
- An HIV Vaccine — Evolving ConceptsNew England Journal of Medicine, 2007
- Structural definition of a conserved neutralization epitope on HIV-1 gp120Nature, 2007
- Rhesus Macaque Polyclonal and Monoclonal Antibodies Inhibit Simian Immunodeficiency Virus in the Presence of Human or Autologous Rhesus Effector CellsJournal of Virology, 2006
- Nonneutralizing Antibodies Are Able To Inhibit Human Immunodeficiency Virus Type 1 Replication in Macrophages and Immature Dendritic CellsJournal of Virology, 2006
- Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti–HIV-1 IgG without induction of maturationBlood, 2006
- Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal AntibodiesJournal of Virology, 2004
- Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1Journal of Virology, 2001
- Identification and Characterization of a Peptide That Specifically Binds the Human, Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody b12Journal of Virology, 2001
- In vivo adaptation of SHIVSF162: Chimeric virus expressing a NSI, CCR5‐specific envelope proteinJournal of Medical Primatology, 1999
- Involvement of the Complement System in Antibody-Mediated Post-exposure Protection Against Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 1998